Division of Clinical Genetics, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, USA.
Department of Pediatrics, University of Missouri - Kansas City School of Medicine, 2401 Gillham Road, Kansas City, MO, USA.
Osteoporos Int. 2024 Jan;35(1):1-10. doi: 10.1007/s00198-023-06843-2. Epub 2023 Nov 20.
Hypophosphatasia (HPP) is a rare inborn error of metabolism that presents variably in both age of onset and severity. HPP is caused by pathogenic variants in the ALPL gene, resulting in low activity of tissue nonspecific alkaline phosphatase (TNSALP). Patients with HPP tend have a similar pattern of elevation of natural substrates that can be used to aid in diagnosis. No formal diagnostic guidelines currently exist for the diagnosis of this condition in children, adolescents, or adults. The International HPP Working Group is a comprised of a multidisciplinary team of experts from Europe and North America who have expertise in the diagnosis and management of patients with HPP. This group reviewed 93 papers through a Medline, Medline In-Process, and Embase search for the terms "HPP" and "hypophosphatasia" between 2005 and 2020 and that explicitly address either the diagnosis of HPP in children, clinical manifestations of HPP in children, or both. Two reviewers independently evaluated each full-text publication for eligibility and studies were included if they were narrative reviews or case series/reports that concerned diagnosis of pediatric HPP or included clinical aspects of patients diagnosed with HPP. This review focused on 15 initial clinical manifestations that were selected by a group of clinical experts.The highest agreement in included literature was for pathogenic or likely pathogenic ALPL variant, elevation of natural substrates, and early loss of primary teeth. The highest prevalence was similar, including these same three parameters and including decreased bone mineral density. Additional parameters had less agreement and were less prevalent. These were organized into three major and six minor criteria, with diagnosis of HPP being made when two major or one major and two minor criteria are present.
低磷酸酯酶症(HPP)是一种罕见的先天性代谢缺陷病,其发病年龄和严重程度各不相同。HPP 是由 ALPL 基因的致病性变异引起的,导致组织非特异性碱性磷酸酶(TNSALP)活性降低。HPP 患者往往具有相似的天然底物升高模式,可用于辅助诊断。目前尚无针对儿童、青少年或成人 HPP 诊断的正式诊断指南。国际 HPP 工作组由来自欧洲和北美的多学科专家组成,他们在 HPP 患者的诊断和管理方面具有专业知识。该小组通过 Medline、Medline In-Process 和 Embase 搜索 2005 年至 2020 年期间的“HPP”和“低磷酸酯酶症”这两个术语,共审查了 93 篇论文,这些论文明确涉及儿童 HPP 的诊断、儿童 HPP 的临床表现或两者兼有。两名审查员独立评估了每篇全文出版物的资格,纳入的研究如果是关于儿科 HPP 诊断或包含已诊断为 HPP 患者的临床方面的叙述性综述或病例系列/报告,则予以纳入。本综述重点关注了由一组临床专家选择的 15 个初始临床表现。纳入文献中一致性最高的是致病性或可能致病性的 ALPL 变异、天然底物升高和早期丧失乳牙。最高的患病率也相似,包括这三个相同的参数,还包括骨矿物质密度降低。其他参数的一致性和普遍性较低。这些参数被分为三大类和六小类,如果存在两个主要标准或一个主要标准和两个次要标准,则可诊断为 HPP。